Equities researchers at Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a research report issued on Friday, MarketBeat reports. The brokerage set an “overweight” rating and a $128.00 price target on the biotechnology company’s stock. Morgan Stanley’s price objective points to a potential upside of 34.61% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. ValuEngine cut Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. BidaskClub cut Ascendis Pharma A/S from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 12th. Wedbush set a $191.00 price objective on Ascendis Pharma A/S and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Zacks Investment Research raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, August 27th. Finally, JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $143.00 to $152.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $146.13.

Shares of ASND stock traded up $2.76 on Friday, reaching $95.09. 296,510 shares of the stock were exchanged, compared to its average volume of 209,346. Ascendis Pharma A/S has a one year low of $53.21 and a one year high of $133.96. The company has a current ratio of 11.59, a quick ratio of 11.59 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average price of $104.36 and a 200 day moving average price of $114.37.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Wednesday, August 28th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.08). Ascendis Pharma A/S had a negative return on equity of 35.99% and a negative net margin of 932.52%. The firm had revenue of $3.61 million for the quarter, compared to the consensus estimate of $0.68 million. As a group, equities research analysts expect that Ascendis Pharma A/S will post -5.36 EPS for the current year.

Institutional investors have recently made changes to their positions in the stock. NumerixS Investment Technologies Inc acquired a new position in Ascendis Pharma A/S in the first quarter valued at about $94,000. Tobam acquired a new position in Ascendis Pharma A/S in the second quarter valued at about $157,000. First Trust Advisors LP acquired a new position in Ascendis Pharma A/S in the second quarter valued at about $215,000. LPL Financial LLC grew its stake in Ascendis Pharma A/S by 6.2% in the second quarter. LPL Financial LLC now owns 2,233 shares of the biotechnology company’s stock valued at $257,000 after acquiring an additional 131 shares during the period. Finally, Flinton Capital Management LLC grew its stake in Ascendis Pharma A/S by 6.7% in the second quarter. Flinton Capital Management LLC now owns 2,304 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 144 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Read More: What is Call Option Volume?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.